Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00309855 · ClinicalTrials.gov registry record · Phase 1
Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT00309855: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT00309855 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00309855, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
This study is being done to understand how testosterone, the major male sex hormone, controls the pituitary gland's secretion of growth hormone (GH). GH is an important metabolic hormone, which controls sugar; fat and protein use in the body and maintains muscle strength and bone calcium content. Both testosterone and GH decline in older men. The age-related fall in these hormones probably contributes to relative frailty, reduced quality of life, bone loss, muscle wasting and impaired sexual function.
Interventions
- DRUG Placebo
- DRUG Testosterone
- DRUG Anastrazole
- DRUG Dutasteride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2005-12 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00309855
The ClinicalTrials.gov registry entry for NCT00309855 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00309855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00309855 about?
NCT00309855 is a clinical study titled "Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men". This study is being done to understand how testosterone, the major male sex hormone, controls the pituitary gland's secretion of growth hormone (GH). GH is an important metabolic hormone, which controls sugar; fat and protein use in the body and maintains muscle strength and bone calcium content. Bo...
What is the current status of trial NCT00309855?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2005-12. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00309855?
The interventions under investigation include: Placebo (DRUG), Testosterone (DRUG), Anastrazole (DRUG), Dutasteride (DRUG).
Who is sponsoring clinical trial NCT00309855?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.